190 related articles for article (PubMed ID: 23160756)
21. Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.
Pierga JY; Petit T; Delozier T; Ferrero JM; Campone M; Gligorov J; Lerebours F; Roché H; Bachelot T; Charafe-Jauffret E; Pavlyuk M; Kraemer S; Bidard FC; Viens P
Lancet Oncol; 2012 Apr; 13(4):375-84. PubMed ID: 22377126
[TBL] [Abstract][Full Text] [Related]
22. [Retrospective analysis of trastuzumab treatment in 141 patients with Her-2 positive breast cancer].
Wang Y; Li JJ; DI GH; Lu JS; Wu J; Liu GY; Hu XC; Wang ZH; Yang WT; Shao ZM
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):864-7. PubMed ID: 21223695
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy response and survival of inflammatory breast cancer by hormone receptor- and HER2-defined molecular subtypes approximation: an analysis from the National Cancer Database.
Liu J; Chen K; Jiang W; Mao K; Li S; Kim MJ; Liu Q; Jacobs LK
J Cancer Res Clin Oncol; 2017 Jan; 143(1):161-168. PubMed ID: 27704268
[TBL] [Abstract][Full Text] [Related]
24. Prognostic Value of HER2 to CEP17 Ratio on Fluorescence In Situ Hybridization Ratio in Patients with Nonmetastatic HER2-Positive Inflammatory and Noninflammatory Breast Cancer Treated with Neoadjuvant Chemotherapy with or without Trastuzumab.
Kogawa T; Fujii T; Wu J; Harano K; Fouad TM; Liu DD; Shen Y; Masuda H; Krishnamurthy S; Chavez-MacGregor M; Lim B; Murthy RK; Valero V; Tripathy D; Ueno NT
Oncologist; 2020 Jun; 25(6):e909-e919. PubMed ID: 32003919
[TBL] [Abstract][Full Text] [Related]
25. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab.
Jones LW; Haykowsky M; Peddle CJ; Joy AA; Pituskin EN; Tkachuk LM; Courneya KS; Slamon DJ; Mackey JR
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1026-31. PubMed ID: 17507633
[TBL] [Abstract][Full Text] [Related]
26. IBC as a Rapidly Spreading Systemic Disease: Clinical and Targeted Approaches Using the Neoadjuvant Model.
Dawood S; Cristofanilli M
J Natl Cancer Inst Monogr; 2015 May; 2015(51):56-9. PubMed ID: 26063888
[TBL] [Abstract][Full Text] [Related]
27. The role of adjuvant monoclonal antibody therapy for breast cancer: rationale and new studies.
Perez EA
Curr Oncol Rep; 2001 Nov; 3(6):516-22. PubMed ID: 11595120
[TBL] [Abstract][Full Text] [Related]
28. Breast cancer: Increasing therapy options for HER2-positive early breast cancer.
Harbeck N
Nat Rev Clin Oncol; 2011 Dec; 9(1):10-2. PubMed ID: 22186934
[No Abstract] [Full Text] [Related]
29. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
[TBL] [Abstract][Full Text] [Related]
30. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial.
van Ramshorst MS; van der Voort A; van Werkhoven ED; Mandjes IA; Kemper I; Dezentjé VO; Oving IM; Honkoop AH; Tick LW; van de Wouw AJ; Mandigers CM; van Warmerdam LJ; Wesseling J; Vrancken Peeters MT; Linn SC; Sonke GS;
Lancet Oncol; 2018 Dec; 19(12):1630-1640. PubMed ID: 30413379
[TBL] [Abstract][Full Text] [Related]
31. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
[TBL] [Abstract][Full Text] [Related]
32. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Lluch A; Tjulandin S; Zambetti M; Moliterni A; Vazquez F; Byakhov MJ; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Magazzù D; Heinzmann D; Steinseifer J; Valagussa P; Baselga J
Lancet Oncol; 2014 May; 15(6):640-7. PubMed ID: 24657003
[TBL] [Abstract][Full Text] [Related]
33. Effects of adding taxane to anthracycline-based neoadjuvant chemotherapy in locally advanced breast cancer.
Rašić A; Sofić A; Bešlija S; Rašić I; Hasanbegović B
Med Glas (Zenica); 2019 Feb; 16(1):77-82. PubMed ID: 30256061
[TBL] [Abstract][Full Text] [Related]
34. A network meta-analysis on the efficacy of HER2-targeted agents in combination with taxane-containing regimens for treatment of HER2-positive metastatic breast cancer.
Xie BJ; Zhu LN; Ma C; Li JB; Dong L; Zhu ZN; Ding T; Gu XS
Breast Cancer; 2020 Mar; 27(2):186-196. PubMed ID: 31529262
[TBL] [Abstract][Full Text] [Related]
35. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
[TBL] [Abstract][Full Text] [Related]
36. Neoadjuvant treatment for HER-2-positive and triple-negative breast cancers.
Sousa B; Cardoso F
Ann Oncol; 2012 Sep; 23 Suppl 10():x237-42. PubMed ID: 22987969
[TBL] [Abstract][Full Text] [Related]
37. Pathological response and circulating tumor cell count identifies treated HER2+ inflammatory breast cancer patients with excellent prognosis: BEVERLY-2 survival data.
Pierga JY; Petit T; Lévy C; Ferrero JM; Campone M; Gligorov J; Lerebours F; Roché H; Bachelot T; Charafe-Jauffret E; Bonneterre J; Hernandez J; Bidard FC; Viens P
Clin Cancer Res; 2015 Mar; 21(6):1298-304. PubMed ID: 25538259
[TBL] [Abstract][Full Text] [Related]
38. Classical CMF regimen as adjuvant chemotherapy for triple-negative breast cancer may be more effective compared with anthracycline or taxane-based regimens.
Wang S; Shi Y; Yuan Z; Wang X; Liu D; Peng R; Teng X; Qin T; Peng J; Lin G; Jiang X
Med Oncol; 2012 Jun; 29(2):547-53. PubMed ID: 21528408
[TBL] [Abstract][Full Text] [Related]
39. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer.
Perez EA; de Haas SL; Eiermann W; Barrios CH; Toi M; Im YH; Conte PF; Martin M; Pienkowski T; Pivot XB; Burris HA; Stanzel S; Patre M; Ellis PA
BMC Cancer; 2019 May; 19(1):517. PubMed ID: 31146717
[TBL] [Abstract][Full Text] [Related]
40. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer.
Estévez LG; Gradishar WJ
Clin Cancer Res; 2004 May; 10(10):3249-61. PubMed ID: 15161677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]